维普中文期刊产品整合服务
意见 帮助
基本检索 作者索引 机构索引 期刊索引
  • 哲学宗教
  • 社会学
  • 政治法律
  • 军事
  • 经济管理
  • 文化科学
  • 语言文字
  • 文学
  • 艺术
  • 历史地理
  • 自然科学总论
  • 理学
  • 天文地球
  • 生物学
  • 医药卫生
  • 农业科学
  • 一般工业技术
  • 矿业工程
  • 石油与天然气工程
  • 冶金工程
  • 金属学及工艺
  • 机械工程
  • 兵器科学与技术
  • 动力工程及工程热...
  • 核科学技术
  • 电气工程
  • 电子电信
  • 自动化与计算机技术
  • 化学工程
  • 轻工技术与工程
  • 建筑科学
  • 水利工程
  • 交通运输工程
  • 航空宇航科学技术
  • 环境科学与工程
时间 1989 - 2010 学科选择学科
题名/关键词 模糊
与 题名/关键词 模糊
重新搜索 在结果中搜索
19篇 您的检索式：作者名="RICHMAN SD"
选中 清除  导出 查看参考文献 查看引证文献 引用追踪 共1页 首页 上一页 第1页 下一页 末页 /1 跳转
    题名 作者 年代 出处 被引量
1Predictive biomarkers ofchemotherapy efficacy in colorectal cancer: results from the UKMRC FOCUS trial显示文摘Braun MS Richman SD Quirke P 2008J Clin Oncol2008，26，16：1
2KRAS and BRAF mutations in advanced colorectal cancer areassociated with poor prognosis but do not precludebenefit from oxaliplatin or irinotecan: results fromthe MRC FOCUS trial 显示文摘Richman SD Seymour MT Chambers P 2009J Clin Oncol2009，27，：1
3KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan:results from the MRC FOCUS trial显示文摘Richman SD Seymour MT Chambers P 2009J Clin Oncol2009，27，：1
4KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan:results from the MRC FOCUS trial显示文摘Richman SD Seymour MT Chambers P 0，，35：1
5Predictive biomarkers of chemotherapy efficacy in colorectal cancer:results from the UK MRC FOCUS trial显示文摘Braun MS Richman SD Quirke P 0，，：1
6Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing显示文摘Richman SD Chambers P Seymour MT 0，，：1
7Predictive biomarkers of chemotherapy efficacy in colorectal cancer:results from the UK MRC FOCUS trial显示文摘Braun MS Richman SD Quirke P 2008J Clin Oncol2008，26，16：1
8KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial显示文摘Richman SD Seymour MT Chambers P 2009J Clin Oncol2009，27，35：1
9KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan : results from the MRC FOCUS trial显示文摘Richman SD Seymour MT 2009J Clin Oncol2009，27，35：1
10Predictive biomarkers of chemotherapy efficacy in colorectal cancer:Results from the UK MRC FOCUS trial显示文摘Braun MS Richman SD Quirke P 2008J Clin Oncol2008，26，16：1
11KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan:results from the MRC FOCUS trial显示文摘Richman SD Seymour MT Chambers P 2009J Clin Oncol2009，27，35：1
12Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial显示文摘Braun MS Richman SD Quirke P 2008J Clin Oncol2008，26，16：1
13Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of muhiple sample testing 显示文摘Richman SD Chambers P Seymour MT 2011Anal Cell Pathol ( Amst )2011，34，12：1
14Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial 显示文摘Braun MS Richman SD Quirke P 2008J Clin Oncol2008，26，16：1
15KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial显示文摘Richman SD Seymour MT Chambers P 2009J Clin Oncol2009，27，35：1
16KRAS and BRAF mutation in advanced colorectal cancer are associated with poor prognosis but do not preclude bene- fit from Oxaliplatin or Irinotecan: results from the MRC FOCUS Trial显示文摘Richman SD Seymour MT Chambers P 2009J Clin Oncol2009，27，35：1
17Association of molecu- lar marker with toxiciy outcomesin a randomized trial of chemo- therapy for advanced colorectal cancer:the FOCUS trial显示文摘Braun MS Richman SD hompson L 2009Clin Oncol2009，27，33：1
18Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial 显示文摘BRAUN MS RICHMAN SD THOMPSON L 2009J Clin Oncol2009，27，33：1
19KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan:results from the MRC FOCUS trial显示文摘Richman SD Seymour MT Chambers P 0，，35：1
返回顶部 每页显示：
共1页 首页 上一页 第1页 下一页 末页 /1 跳转
goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费